Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 20,000 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director James R. Tobin sold 20,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the transaction, the director now owns 173,146 shares in the company, valued at $27,587,352.18. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

TransMedics Group Trading Up 0.6 %

NASDAQ:TMDX traded up $1.04 on Friday, reaching $162.89. 742,292 shares of the company’s stock were exchanged, compared to its average volume of 769,601. The firm has a market capitalization of $5.43 billion, a price-to-earnings ratio of -476.03 and a beta of 1.99. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $171.98. The company has a quick ratio of 8.76, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The business has a fifty day moving average of $145.03 and a 200-day moving average of $113.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The firm had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business’s quarterly revenue was up 117.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.03) earnings per share. As a group, analysts expect that TransMedics Group, Inc. will post 1.1 earnings per share for the current year.

Institutional Trading of TransMedics Group

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC increased its holdings in TransMedics Group by 106.7% during the 2nd quarter. Renaissance Technologies LLC now owns 131,899 shares of the company’s stock worth $19,867,000 after purchasing an additional 68,100 shares during the period. Total Clarity Wealth Management Inc. purchased a new stake in shares of TransMedics Group during the second quarter worth approximately $334,000. J.W. Cole Advisors Inc. acquired a new stake in TransMedics Group in the second quarter valued at approximately $2,155,000. O Neil Global Advisors Inc. purchased a new position in TransMedics Group in the second quarter worth approximately $1,604,000. Finally, Federated Hermes Inc. acquired a new position in TransMedics Group during the 2nd quarter worth approximately $3,349,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on TMDX. Cantor Fitzgerald started coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Canaccord Genuity Group increased their price target on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. TD Cowen boosted their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Finally, Stephens increased their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $166.88.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.